Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TaoWeave (TWAV) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for TaoWeave (TWAV) over the last 16 years, with Q3 2025 value amounting to $10.9 million.

  • TaoWeave's Liabilities and Shareholders Equity rose 8177.87% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.0 million, marking a year-over-year increase of 3509.82%. This contributed to the annual value of $5.3 million for FY2024, which is 2382.67% down from last year.
  • As of Q3 2025, TaoWeave's Liabilities and Shareholders Equity stood at $10.9 million, which was up 8177.87% from $13.1 million recorded in Q2 2025.
  • Over the past 5 years, TaoWeave's Liabilities and Shareholders Equity peaked at $34.9 million during Q2 2021, and registered a low of $4.8 million during Q1 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $8.0 million (2023), whereas its average is $13.5 million.
  • As far as peak fluctuations go, TaoWeave's Liabilities and Shareholders Equity tumbled by 8021.11% in 2022, and later surged by 10720.06% in 2025.
  • TaoWeave's Liabilities and Shareholders Equity (Quarter) stood at $28.6 million in 2021, then crashed by 80.21% to $5.7 million in 2022, then grew by 22.33% to $6.9 million in 2023, then dropped by 23.83% to $5.3 million in 2024, then skyrocketed by 106.52% to $10.9 million in 2025.
  • Its Liabilities and Shareholders Equity was $10.9 million in Q3 2025, compared to $13.1 million in Q2 2025 and $4.8 million in Q1 2025.